Using computer-aided drug discovery tools such as quantitative structure-activity relation (QSAR) models and structure-based virtual screening, we previously searched for drug candidates with a predicted ability to inhibit the EGFR/PI3K pathway and to cross the blood–brain barrier (BBB) for glioma treatment [39]. Here, EGFR is linked to central nervous system cancer.